Aclaris Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Aclaris Therapeutics

08/05/2023 14:32

* Aclaris Therapeutics Inc  ACRS.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended in March. The
mean expectation of nine analysts for the quarter was for a loss
of 44 cents per share.
    * Revenue rose 74% to $2.53 million from a year ago;
analysts
expected $1.75 million. 
    * Aclaris Therapeutics Inc's reported EPS for the quarter
was a
loss of 42 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aclaris Therapeutics Inc shares had risen by 11.0% this
quarter and lost 43.0% so far this year.
    * The company reported a quarterly loss of $28.16 million.
    * Wall Street's median 12-month price target for Aclaris
Therapeutics Inc is $30.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.44          -0.40          Beat
 Dec. 31 2022      -0.45          -0.41          Beat
 Sep. 30 2022      -0.40          -0.30          Beat
 Jun. 30 2022      -0.36          -0.31          Beat